Compare Citius Pharmaceuticals Inc (CTXR) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Invesco Solar ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Invesco Solar ETF trades at $44.02 (market cap $894.08M). The key difference: Invesco Solar ETF is far larger — about 65.6× Citius Pharmaceuticals Inc's market cap, and Invesco Solar ETF is more actively traded (370,994 versus 132,438). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Invesco Solar ETF for 34 Days on average.
| CTXR | TAN | |
|---|---|---|
Market Cap | $13.62M | $894.08M |
Volume | 132,438 | 370,994 |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $73.95 |
52-Week Low | $0.48 | $43.00 |
Typical Hold Time | 16 Days | 34 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
TAN (Invesco Solar ETF) is trading at $43.53, down 1.96% amid sector-wide pressure from high borrowing costs impacting solar project financing. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF faces headwinds from solar industry volatility, price deflation, and margin erosion, having underperformed the S&P 500 by 112% over five years according to Seeking Alpha analysis from August 2026.
Outlook remains challenging with persistent sector headwinds including interest rate sensitivity and market saturation risks. Investment opportunity exists in long-term renewable energy transition, but requires tolerance for high volatility and deeper drawdowns compared to traditional energy ETFs. Key risks include policy uncertainty, grid adaptation costs, and competitive pressure from broader clean energy alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
